ArticleCancer chemotherapy and pharmacology2012

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.

Federica Grosso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.